KABAKOFF DAVID S 4
4 · NextCure, Inc. · Filed Jun 24, 2025
Insider Transaction Report
Form 4
NextCure, Inc.NXTC
KABAKOFF DAVID S
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-06-20+28,050→ 28,050 totalExercise: $0.47Exp: 2035-06-19→ Common Stock (28,050 underlying)
Footnotes (1)
- [F1]The option vests in full on the earlier of June 20, 2026 and the date of the 2026 Annual Meeting of Stockholders.